Font: Financial Modeling Prep • May 13, 2026
Evolv Technologies Holdings is a leading security technology company. It specializes in developing and selling advanced AI-powered weapon screening systems. These innovative systems are engineered to efficiently detect potential threats without requiring individuals to stop or empty their pockets, enhancing both security and user experience. Evolv primarily serves critical sectors such as education, healthcare, sports, and entertainment venues, providing crucial public safety solutions.
On May 13, 2026, prominent analyst firm Craig-Hallum reaffirmed its "Buy" rating for Evolv, noting the stock price at $5.80. The firm expressed confidence that the company is "well positioned" to exceed its financial goals for the 2026 fiscal year. This optimistic analyst outlook is underpinned by Evolv's recent robust performance and sustained market demand for its security solutions.
This positive rating is strongly supported by Evolv's impressive financial results. As reported by MarketBeat, Evolv achieved a substantial 45% year-over-year increase in first-quarter revenue, reaching $46.30 million. This significant figure not only demonstrates strong revenue growth but also surpassed analyst expectations by over 5%. Following these encouraging results, the company proactively raised its revenue forecast for the full year of 2026, indicating continued confidence in its growth trajectory.
Evolv's robust subscription business also highlights significant growth. Its Annual Recurring Revenue (ARR), a key indicator of predictable income from subscriptions, surged by 20% to $127.30 million. Furthermore, as reported by Zacks, Evolv announced a smaller-than-expected quarterly loss of $0.03 per share, a notable improvement compared to an anticipated loss of $0.06 per share. This marks the third time in four quarters that Evolv has successfully beaten earnings estimates, showcasing consistent operational efficiency.
Beyond revenue and subscription growth, Evolv's profitability metrics are also showing strong improvement. Adjusted EBITDA, a crucial measure of a company's operating profit, reached $3.90 million for the quarter, a significant improvement from $2.10 million reported a year ago. CEO John Kedzierski emphasized that these results "reflect our progress in building a disciplined and predictable business," as highlighted by Business Wire, reinforcing confidence in Evolv's financial health and strategic direction.
|
ALP§>
AlphaTON Capital Corp. Common Stock
|
$0.38
43.34%
|
|
EZGO§>
EZGO Technologies Ltd.
|
$0.03
-14.64%
|
|
SOXS§>
Direxion Daily Semiconductor Bear 3X ETF
|
$8.22
-1.55%
|
|
SRXH§>
SRx Health Solutions Inc.
|
$0.17
12.10%
|
|
QUCY§>
Mainz Biomed N.V.
|
$1.69
26.12%
|
|
HAO§>
Haoxi Health Technology Limited
|
$0.03
-19.71%
|
|
ONDS§>
Ondas Holdings Inc.
|
$9.87
11.37%
|
|
POET§>
POET Technologies Inc.
|
$19.26
34.00%
|
|
NOK§>
Nokia Oyj
|
$14.62
-0.61%
|
|
EDBL§>
Edible Garden AG Incorporated
|
$0.46
23.63%
|